| All 2006 Releases |
|---|
 |
Osiris Therapeutics Secures Long-Term Tissue Supply Agreement for the Osteocel(R) Product Line
12-14-06
11.9 KB
|
| |
BALTIMORE, Dec 14, 2006 (BUSINESS WIRE) -- Osiris Therapeutics, Inc. (NASDAQ:OSIR) and AlloSource announced today that they have reached a multi-year agreement for the supply of orthopedic tissue. Under the terms of the agreement, AlloSource commits to provide bone matrix to Osiris for use in the production of its Osteocel product line. AlloSource ...
|
|
Osiris Therapeutics Provides Update on Phase II Trial Evaluating PROCHYMAL(TM) for the Treatment of Acute Graft vs. Host Disease
12-09-06
15.0 KB
|
| |
BALTIMORE, Dec 09, 2006 (BUSINESS WIRE) -- Osiris Therapeutics, Inc. (NASDAQ:OSIR) announces follow-on data for its ongoing Phase II trial evaluating PROCHYMAL for the treatment of acute Graft vs. Host Disease. The study found that patients were twice as likely to have total clinical resolution of their disease when PROCHYMAL was added to steroid t...
|
|
Osiris Therapeutics to Present at Lazard Life Sciences Conference
11-22-06
8.6 KB
|
| |
BALTIMORE, Nov 22, 2006 (BUSINESS WIRE) -- Osiris Therapeutics, Inc. (NASDAQ:OSIR) announced today that C. Randal Mills, Ph.D., President and CEO, will be presenting at the Lazard Capital Markets Annual Life Sciences Conference on November 29, 2006 at the New York Palace Hotel. The presentation is scheduled for 3:00 PM, EST. A live web cast may be ...
|
|
Osiris Therapeutics Reports Positive Phase II Results Using PROCHYMAL(TM) for the Treatment of Acute Graft vs. Host Disease
11-09-06
14.7 KB
|
| |
BALTIMORE, Nov 09, 2006 (BUSINESS WIRE) -- Osiris Therapeutics, Inc. (NASDAQ:OSIR) announced positive results from a 32 patient Phase II study using PROCHYMAL for the treatment of acute Graft vs. Host Disease or GVHD. In the study, 29 of 31, or 94% of evaluable patients responded after receiving two infusions of PROCHYMAL. More significantly, 23 pa...
|
|
Osiris Therapeutics Successfully Completes Private Placement with Friedli Corporate Finance
11-08-06
12.9 KB
|
| |
BALTIMORE, Nov 08, 2006 (BUSINESS WIRE) -- Osiris Therapeutics, Inc. (NASDAQ:OSIR), as previously announced on November 2, 2006, raised $20 million of newly issued convertible debt led by Friedli Corporate Finance, Inc. in Switzerland.
On October 30, 2006, Osiris issued $20 million in convertible promissory notes to several Swiss investors, pur...
|
|
Osiris Announces Third Quarter Results with Osteocel(R) Sales Growth of 50%
11-02-06
21.9 KB
|
| |
BALTIMORE, Nov 02, 2006 (BUSINESS WIRE) -- Osiris Therapeutics, Inc. (NASDAQ: OSIR), announced its financial results for the third quarter and nine months ended September 30, 2006.
Highlights
-- Osteocel sales increase by 50% or more for the 5th consecutive quarter
-- Osiris makes significant progress expanding its Phase 3 trial evalu...
|
|
Osiris Announces Third Quarter 2006 Financial Results Conference Call
10-31-06
9.2 KB
|
| |
BALTIMORE, Oct 31, 2006 (BUSINESS WIRE) -- Osiris Therapeutics, Inc. (NASDAQ:OSIR) will report its financial results for the third quarter ended September 30, 2006, after the close of trading on the NASDAQ Global Market on Thursday November 2, 2006. C. Randal Mills, Ph.D., President and Chief Executive Officer, and Cary J. Claiborne, Chief Financia...
|
|
Osiris Therapeutics Reports Positive Phase II Results Using PROCHYMAL(TM) in Treatment-Resistant Crohn's Disease
10-19-06
14.4 KB
|
| |
BALTIMORE, Oct 19, 2006 (BUSINESS WIRE) -- Osiris Therapeutics (NASDAQ:OSIR) announced positive results from a pilot phase II study using PROCHYMAL for the treatment of patients with moderate to severe Crohn's disease who had failed to respond to standard treatments such as steroids and infliximab (Remicade(R)). In the study, every patient evaluate...
|
|
Osiris is Granted European Manufacturing Certification for PROCHYMAL(TM)
10-17-06
11.5 KB
|
| |
BALTIMORE, Oct 17, 2006 (BUSINESS WIRE) -- Osiris Therapeutics, Inc. (NASDAQ:OSIR) has received manufacturing authorization to distribute PROCHYMAL into Europe for its Phase III clinical trial. Distribution of product in Europe requires Good Manufacturing Practice certification, which was granted by a European auditor after a comprehensive review o...
|
|
Osiris Therapeutics Receives Approval from Health Canada to Conduct Phase III Clinical Trial for Lead Stem Cell Drug
10-11-06
11.1 KB
|
| |
BALTIMORE, Oct 11, 2006 (BUSINESS WIRE) -- Osiris Therapeutics, Inc. (NASDAQ:OSIR) has received regulatory approval to expand patient enrollment into Canada for its ongoing Phase III pivotal trial evaluating PROCHYMAL(TM) for the treatment of Graft vs. Host Disease.
Graft vs. Host Disease or GVHD is a life threatening immunological reaction tha...
|
|
